Cargando…

DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment

SIMPLE SUMMARY: Liquid biopsy is a highly useful tool for the management of NSCLC patients and could provide valuable information on early detection of resistance to osimertinib. Epigenetic biomarkers are very promising for the early diagnosis, prognosis, and prediction of drug response in many type...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ntzifa, Aliki, Londra, Dora, Rampias, Theodoros, Kotsakis, Athanasios, Georgoulias, Vassilis, Lianidou, Evi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656722/ https://www.ncbi.nlm.nih.gov/pubmed/34885084 http://dx.doi.org/10.3390/cancers13235974

Ejemplares similares

Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR
por: Ntzifa, Aliki, et al.
Publicado: (2021)

PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)
por: Pantazaka, Evangelia, et al.
Publicado: (2022)

Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients
por: Ntzifa, Aliki, et al.
Publicado: (2021)

Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy
por: Kallergi, Galatea, et al.
Publicado: (2022)

USP44 Promoter Methylation in Plasma Cell-Free DNA in Prostate Cancer
por: Londra, Dora, et al.
Publicado: (2021)

Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer
por: Markou, A. N., et al.
Publicado: (2023)

DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection
por: Markou, Α., et al.
Publicado: (2022)

Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer
por: Chimonidou, Maria, et al.
Publicado: (2017)

PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients’ CTCs
por: Sklias, Thodoris, et al.
Publicado: (2022)

Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer
por: Tserpeli, Victoria, et al.
Publicado: (2021)

Immune Checkpoint and EMT-Related Molecules in Circulating Tumor Cells (CTCs) from Triple Negative Breast Cancer Patients and Their Clinical Impact
por: Vardas, Vasileios, et al.
Publicado: (2023)

PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study
por: Tzanikou, Eleni, et al.
Publicado: (2019)

KMT2C promoter methylation in plasma‐circulating tumor DNA is a prognostic biomarker in non‐small cell lung cancer
por: Mastoraki, Sofia, et al.
Publicado: (2020)

Metabolism-Related Gene Expression in Circulating Tumor Cells from Patients with Early Stage Non-Small Cell Lung Cancer
por: Zafeiriadou, A., et al.
Publicado: (2022)

Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients
por: Katsarou, Spyridoula D., et al.
Publicado: (2022)

Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients
por: Strati, Areti, et al.
Publicado: (2019)

RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer
por: Strati, Areti, et al.
Publicado: (2021)

Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2022)

Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer
por: Buszka, Karolina, et al.
Publicado: (2022)

Resolving DNA Damage: Epigenetic Regulation of DNA Repair
por: Karakaidos, Panagiotis, et al.
Publicado: (2020)

Clinical Activity of an hTERT-Specific Cancer Vaccine (Vx-001) in “Immune Desert” NSCLC
por: Pateras, Ioannis S., et al.
Publicado: (2021)

Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook
por: Lianidou, Evi
Publicado: (2021)

Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements
por: Kallergi, G., et al.
Publicado: (2018)

Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Papadaki, Maria A., et al.
Publicado: (2021)

Combinatorial Power of cfDNA, CTCs and EVs in Oncology
por: Keup, Corinna, et al.
Publicado: (2022)

A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of CST6 promoter methylation in clinical samples
por: Dimitrakopoulos, Lampros, et al.
Publicado: (2012)

Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer
por: Zavridou, Martha, et al.
Publicado: (2021)

Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients
por: Liu, Haiyan E., et al.
Publicado: (2020)

Generation of Non-Small Cell Lung Cancer Patient-Derived Xenografts to Study Intratumor Heterogeneity
por: Kanaki, Zoi, et al.
Publicado: (2021)

Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
por: Kejík, Zdeněk, et al.
Publicado: (2021)

ESR1 NAPA Assay: Development and Analytical Validation of a Highly Sensitive and Specific Blood-Based Assay for the Detection of ESR1 Mutations in Liquid Biopsies
por: Stergiopoulou, Dimitra, et al.
Publicado: (2021)

Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment
por: Su, Po‐Lan, et al.
Publicado: (2019)

Detecting expression of 5T4 in CTCs and tumor samples from NSCLC patients
por: Pirie-Shepherd, Steven R., et al.
Publicado: (2017)

The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization
por: Kallergi, Galatea, et al.
Publicado: (2019)

RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA
por: Giannopoulou, Lydia, et al.
Publicado: (2017)

Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA
por: Yaghoubi Naei, Vahid, et al.
Publicado: (2023)

Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer
por: Stergiopoulou, Dimitra, et al.
Publicado: (2023)

Evaluation of Monocarboxylate Transporter 4 (MCT4) Expression and Its Prognostic Significance in Circulating Tumor Cells From Patients With Early Stage Non-Small-Cell Lung Cancer
por: Markou, Athina, et al.
Publicado: (2021)

DNA hypomethylation silences antitumor immune genes in early prostate cancer and CTCs
por: Guo, Hongshan, et al.
Publicado: (2023)

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
por: Yamaguchi, Ou, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_76hvkg3l9uqajd0e12j8f53beh